Jan Niclas Wester

Scintomics GmbH is a privately held German company that specializes in innovative targeted theranostics and corresponding radiopharmaceutical technologies for personalized cancer care. The company is based in Graefelfing, Germany and was founded in 2006. The company's pipeline includes functional diagnostics and radiotherapeutics such as pentixafor and pentixather for theranostics of lymphoproliferative diseases and theridat for adrenocortical cancer. The company's groundbreaking radiohybrid technology and its first lead compound rhpsma-7 allow the true bridging of functional imaging and therapy. Scintomics considers the license agreement, the future collaboration with Blue Earth Diagnostics, and the further adaption of the radiohybrid technology to other targeted cancer theranostics as an important milestone towards its strong positioning as a radiopharmaceutical development specialist. The CEOs are Jan Niclas Wester and Andrea Maugg.